The Healing Power of Botanical Therapeutics®


Herborium Group Moves Forward on Its Commercialization and Promotional Initiatives

Press Release: Herborium Group, Inc. –  Thursday, Jul 19, 2012 8:00 AM EDT

FORT LEE, N.J., July 19, 2012 /PRNewswire/ -- Herborium Group, Inc., (HBRM), a Botanical Therapeutics® Company has presently discontinued its talks with China Health Resource Inc. Herborium has recently experienced a strong growth and shall focus on the growing near term opportunities resulting from other partnerships and from commercialization of its new energy and sexual health products this coming Fall. The China Health Resource offer did not reflect a rapidly growing value of Herborium resulting from increase in present revenues and near future revenue potential of a Kamasutra LLC partnership with its over $4 Billion market in a sector of herbal vodka, $4.5 Billion and growing market potential for sexual health products, and $8 Billion market potential for Herborium all herbal Energy Drink entering the market in the Fall of 2012. "We are extremely excited about Herborium's near term and long term growth opportunities. Furthermore, those opportunities are not a year but mere weeks ahead. With already realized increase in revenues and visibility of AcnEase®, our proprietary acne treatment, weeks from the launch of Kamasutra promotional campaign and our own unique sexual health products, and already publicized energy product scheduled to enter the market in this Fall, we are ideally positioned to make Herborium a significant player in the Botanical Therapeutics® sector in 2012. The recent hiring of the top Public Relations firm, SSPR, provides for a very aggressive publicity schedule to support our activities and for building the company value through top media presence," stated Dr. Agnes Olszewski , CEO and Chairwomen of Herborium Group, Inc. About Herborium Group, Inc. Herborium Group, Inc., a Botanical Therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company uses clinical validation to establish and maintain a differential advantage. The company sales its products in the US and Europe. For more information, please visit and One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events. The Company urges investors to review the risks and uncertainties contained within its filings with the OTC Markets and/or Securities and Exchange Commission. For more information please inquire:



Information provided on about medical conditions, symptoms, and related products is not intended to be a substitute for professional medical advice. Visitors to this site should not use this information to diagnose or treat a health problem, symptom, concern or disease without consulting with their individual qualified healthcare provider. Statements contained on this website have not been evaluated by the FDA. Herborium products are not intended to diagnose, heal, cure or prevent disease.